Search
Alogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalChemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. … Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4).
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedIn addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS]. … Moreover, the agent is capable of demonstrating antioxidant effects that make it a popular component to include in cosmetics and pharmaceuticals as well.
Categories: Compounds used in a research, industrial, or household setting, Vitamins (Fat Soluble)Pentazocine
go.drugbank.com/drugs/DB00652ApprovedVet approvedIt is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
Lasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigational[A187316] Triptans abort migraines via action at several serotonin receptors, including 5-HT<sub>1D</sub> and 5-HT<sub>1B</sub> receptors, and activity at the 5-HT<sub>1B</sub> receptor has been specifically … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Categories: Serotonin (5-HT) 1F Receptor AgonistsArgatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalThe American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary … Argatroban is a direct, selective thrombin inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexEnasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … gene, which is a recurrent mutation detected in 12-20% of adult patients with AML [A20344, A20345].
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic IndexVincristine
go.drugbank.com/drugs/DB00541ApprovedInvestigationalbecause of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy). … It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar.
Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: SULFATO DE VINCRISTINA 1 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCIÓN INYECTABLE.Betula pendula tar oil
go.drugbank.com/drugs/DB11361ApprovedNutraceuticalBetula pendula tar oil is an essential oil found in the buds of the plant with the same name. … The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere.
Alectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. … Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.